Why AI Isn’t Enough for Regulatory Translation in MedTech
From Submission to Approval: Understanding the Translation Starting Line
When medical device manufacturers aim to enter a foreign market, the process of regulatory translation doesn’t begin with translating documents. It begins earlier—with understanding the approval requirements of the target market.
Whether you’re targeting the U.S., EU, or another region, the certification process requires detailed documentation tailored to that market’s regulatory framework. For instance, in the U.S., the FDA outlines submission requirements through the 510(k) or PMA pathways. In the EU, the MDR governs device approvals, requiring a technical file that includes labeling, IFUs, and clinical data.
Understanding these requirements often means interpreting complex regulatory texts in a foreign language. Before any translation begins, the manufacturer must gather, assess, and adapt its documentation to align with the expectations of the foreign regulator. Errors or misunderstandings at this stage can cause cascading issues down the line.
Figure 1: Language support throughout the medical device approval process
The Real Cost of AI Translation Errors in Regulated Industries
Translation isn’t just a box to tick—it’s a strategic function with financial consequences. Bringing a device to a new market involves coordinated efforts across regulatory, commercial, and marketing teams. Many activities—market research, sales channel development, even training—are started in parallel with the approval process.
Consider that a 510(k) submission in the U.S. can cost upwards of $30,000 to $100,000, excluding internal resource allocation. In Europe, MDR compliance for Class II and III devices can exceed €100,000 when factoring in Notified Body fees and documentation. If poorly translated documents cause a rejection or delay, the sunk cost includes not just the rework, but also the missed revenue, lost market opportunity, and potential erosion of brand trust.
These are the real costs of AI translation when it’s used without expert human oversight: delayed product launches, missed forecasts, and legal vulnerability.
Why Accuracy Alone Isn’t Enough
In regulatory contexts, “accuracy” must go beyond word-for-word correctness. ISO 17100, the international standard for translation services, defines a comprehensive, auditable process that includes:
- Qualified translators and revisers
- Project scoping and terminology management
- Review and verification by a second linguist
- Documentation of decisions and approvals
GEF is ISO 17100-certified and also ISO 13485:2016-certified, meaning we operate within these strict standards not only for translation but also for quality management specific to medical devices. We don’t just deliver translated text; we deliver traceable, validated outputs that stand up to scrutiny. This ensures that submissions are not only accurate but also aligned with the expectations of global regulators.
Figure 2: ISO 17100 workflow
Translation Traceability: Why It Matters
Traceability in translation means having a clear record of who translated, reviewed, and approved each component—and how. In regulatory disputes, this documentation serves as a safeguard.
AI systems can’t provide legally meaningful authorship or accountability. In contrast, a professional language service provider like GEF is a contractual partner. We offer:
- Clearly defined scopes of work
- Human experts accountable for quality
- Negotiated SLAs and revision protocols
- Transparent credentials and certifications
This “human agency” is crucial when a translation is challenged or must be defended. You have a partner who can respond, justify, and adjust—not just an algorithm.
Your Regulatory Translation Checklist
By treating translation as a compliance-critical process, manufacturers reduce risk, accelerate approvals, and ensure global readiness.
Further Reading
